Abbott has announced results from the FreeDM2 randomised controlled trial (RCT), indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre c ...

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.

MercadoLibre (NASDAQ:MELI) executives highlighted “robust operating trends” to close 2025, driven by faster growth in its ...

Latin America's leading e-commerce and fintech platform, today announced fourth quarter and full year 2025 financial results. This quarter, Mercado Libre delivered net revenue and financial income of ...

Abbott has announced that its latest continuous glucose monitor, the FreeStyle Libre 3, is now covered under Medicare. Following news in April that the FDA cleared a separate handheld reader for ...

The FDA designated this a Class I Recall after 860 serious injuries and 7 deaths were reported related to falsely low glucose readings. Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and ...

Investing.com - TD Cowen has reiterated its Buy rating and $145.00 price target on Abbott Labs (NYSE:ABT) ahead of the company’s fourth quarter 2025 earnings report. Currently trading at $121.28, ...

mylife Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes mylife Loop ...

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist, 1 a groundbreaking feature within the Libre app 5 designed to help the ...

Traditional food logging apps offer feedback after the fact—Libre Assist 1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist 1 leverages AI to predict how food ...